Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.

From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions.

Patient characteristics, safety and outcomes were collected.

Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9. 01 and 15. 7 months, respectively. No unexpected adverse events were reported.

Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.

Future oncology (London, England). 2015 Nov 06 [Epub ahead of print]

Annalisa Guida, Cristina Masini, Michele Milella, Giuseppe Di Lorenzo, Matteo Santoni, Veronica Prati, Camillo Porta, Laura Cosmai, Donatella Donati, Cinzia Del Giovane, Pasquale Mighali, Roberto Sabbatini

Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy. , AO Santa Maria Nuova, Reggio Emilia, Italy. , Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy. , Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy. , Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti Umberto I, Ancona, Italy. , Oncologia Medica a Direzione Universitaria, Fondazione del Piemonte per l'Oncologia, Istituto per la Ricerca e Cura del Cancan Candiolo, Torino, Italy. , Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy. , Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy. , Unità Operativa Oncologia, Azienda Ospedaliero-Universitaria, Ferrara, Italy. , Statistics Unit, Department of Clinical, Diagnostic & Public Health Medicine, University of Modena & Reggio Emilia, Modena, Italy. , Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy. , Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe